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Inhibition of 5-Lipoxygenase–activating Protein (FLAP) Reduces Pulmonary 
Vascular Reactivity and Pulmonary Hypertension in Hypoxic Rats
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Chronically elevated shear stress and inflammation are im-
portant in hypertensive lung vessel remodeling. We postu-
late that 5-lipoxygenase (5-LO) is a molecular determinant
of these processes. Immunohistology localized the 5-LO to
macrophages of normal and chronically hypoxic rat lungs
and also to vascular endothelial cells in chronically hypoxic
lungs only. In situ hybridization of normal and chronically
hypoxic lungs demonstrated that 5-LO mRNA is expressed
in macrophages. Rats hypoxic for 4 wk–developed pulmo-
nary hypertension increased translocation of the lung 5-LO
from the cytosol to the membrane fraction and increased
levels of lung tissue 5-lipoxygenase–activating protein (FLAP).
 













]-2,2-dimethylpropanoic acid (MK-886), inhib-
ited the acute angiotensin II and hypoxia-induced pulmo-
nary vasoconstriction in vitro and the development of chronic
hypoxic pulmonary hypertension in rats in vivo. Mice bred
with the deletion of the 5-LO enzyme (5-LO knockout) de-
veloped less right heart hypertrophy than age-matched 5-LO
competent mice. Our results support the hypothesis that the
5-LO is involved in lung vascular tone regulation and in the
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Chronic pulmonary hypertension leads to remodeling of the
lung vessels (1, 2). In human pulmonary hypertension and in
animal models of experimental pulmonary hypertension, vaso-
constriction causes vascular smooth muscle hypertrophy (1).
In addition, high shear stress, inflammatory mediators, and
growth factors participate in pulmonary endothelial cell dam-
age and endothelial cell proliferation (1–4). Hypoxic vasocon-
striction is involved in the development of pulmonary hyper-
tension, which accompanies many chronic lung diseases;
whereas, nonhypoxic vasoconstriction due to unknown media-
tors may play a role in the rare form of unexplained, primary
pulmonary hypertension (5, 6).
Our interest in the molecular mechanisms of pulmonary
vascular remodeling is understandable when one considers the
short survival time of patients with severe pulmonary hyper-
tension (7). Although there are no animal models of primary
pulmonary hypertension, the chronic pulmonary hypertension
in animal models likely uses pathogenetic mechanisms rele-
vant for the human disorder.
Chronic exposure of rats to hypoxia (3, 4) or a single injec-
tion of the alkaloid monocrotaline generates significant pul-





 in pulmonary hypertension is based on the fact
that agents that block the production of leukotrienes (LT) in-
hibit the development of pulmonary hypertension both in the
hypoxia and the monocrotaline rat model (8–10). Confounding
aspects of earlier studies were that the agents used to treat pul-
monary hypertension were not specific, and little is known
about the pathophysiological role of lung 5-LO. The consensus
is that inflammatory cells, neutrophils, and macrophages are
the source of 5-LO in the lung and that these cells can generate
LT directly or via transcellular metabolism (11–15). Both
chronic hypoxia and intravascular inflammation activate cyto-
kine production in the lung (4, 16, 17). The final signal trans-
duction pathways leading to vascular remodeling in lung tissue
may be similar or overlapping, whether triggered by increased
shear stress, hypoxia, or inflammatory cells.
Here we investigate the role of 5-LO in pulmonary hyper-













an inhibitor of the 5-LO:FLAP (5-lipoxygenase–activating
protein) interactions (18, 19), decreases pulmonary vascular
tone and inhibits the development of chronic hypoxic pulmo-
nary hypertension. We have used antibodies (20) and a cDNA
probe (21) to localize 5-LO and FLAP proteins and the 5-LO
mRNA in the lung. The data indicate that the alveolar mac-
rophages are the main source of lung 5-LO in normal and hy-
poxic rats; however, 5-LO also occurs in the endothelium of
hypoxic rats. Further, we find evidence for activation of the 5-LO
in chronically hypoxic lung tissue homogenates as demon-
strated by the cytosol to membrane translocation of the en-
 
Address correspondence to Norbert F. Voelkel, Pulmonary and Crit-
ical Care Division (C272), University of Colorado Health Sciences
Center, 4200 E. Ninth Avenue, Denver, CO 80262. Phone: 303-270-
4211; FAX: 303-270-5632.
 
Received for publication 6 October 1995 and accepted in revised




Abbreviations used in this paper:
 
 FLAP, 5-lipoxygenase–activating





















zyme. Lastly, 5-LO–deficient (22), chronically hypoxic mice de-






5-LO deficient mice (22) and male Sprague-Dawley rats
(Harlan Sprague Dawley, Inc., Indianapolis, IN) were maintained at
the University of Colorado Health Sciences Center Animal Resource
Center. All animal experiments were conducted under protocols re-
viewed and approved by the University of Colorado Health Sciences
Center Animal Care Committee.
 
Immune localization of 5-LO and FLAP in rat lungs.
 
Frozen sec-
tions of rat lungs were immunostained as described (23). The anti–
5-LO polyclonal antibody LO32 (20) was used at a 1:50 dilution. Con-
trols consisted of normoxic and hypoxic lungs incubated with a normal
rabbit serum at the same dilution as used for the anti–5-LO antibod-
ies. Specificity was further assessed by absorption of the LO32 anti-
sera with 5-LO. Anti–5-LO antiserum was incubated with twofold ex-

















, the supernatant was incubated with the
frozen sections of rat lung. Unabsorbed antibody staining was per-
formed in parallel slides. FLAP immunolocalization was performed
in paraffin-embedded, formalin-fixed rat lungs. After paraffin re-
moval in xylene, the sections were rehydrated and submitted to mi-
crowave treatment (800 W/10 min) in 10 mM citric acid monohydrate.
 








 for 25 min,
the sections were exposed to anti-FLAP polyclonal antibody (20) (1:600





mRNA in situ hybridization was performed









 untranslated sequence was ex-
cised with EcoRI and XbaI of p5LX and subcloned into EcoRI/XbaI
digested pcDNA-III which was obtained from Invitrogen Corp. (San
Diego, CA). Digoxigenin-labeled antisense and sense probes were
synthesized from the T7 and SP-6 polymerase promoters, respectively
(Genius IV kit; Boehringer Mannheim Biochemicals, Indianapolis,
IN). The digoxigenin-labeled cRNA probes underwent alkaline hy-





C and was developed under dark conditions for 12 h.
 
Immunochemical detection of 5-LO and FLAP in lung samples.
 
Polyclonal rabbit antisera specific for 5-LO and for FLAP were pro-
vided by Dr. Jilly Evans (Merck-Frosst, Pointe Claire-Dorval, Canada).
Goat anti–rabbit antiserum conjugated to horseradish peroxidase was
obtained from Bio-Rad Laboratories (Richmond, CA), chemilumi-
nescent reagents were from Amersham Corp. (Arlington Heights,
IL), protein assay reagents were from Pierce (Rockford, IL) and fish
skin gelatin was obtained from Norland Products (New Brunswick,



















30 s on ice (Tekmar Tissumizer, Cincinnati OH). Disrupted




20 s (power setting 3, 75% duty









C. After centrifugation, supernatant fractions designated to-





(250 mM Tris-HCl, pH 6.8, 5% wt/vol SDS, 50% glycerol, 100 mg/ml





C while the protein content of each fraction was determined. The









C to generate a supernatant fraction (Cytosol) and pellet fraction
(Membrane). A portion of the resulting cytosol and membrane frac-




 electrophoresis buffer, boiled
for 5 min, and held on ice while the protein concentration of each
fraction was quantified. To determine the relative 5-LO content of
the various fractions, samples of total protein, cytosol, and membrane
fractions containing equal amounts of protein were applied to 10%
acrylamide gels with a 4% stacking gel and separated by electro-
phoresis. Samples of the membrane fractions containing equal quan-
tities of protein were applied to 15% separating, 4% stacking gels to
determine the relative FLAP content of the samples. After electro-
phoresis, proteins were transferred to nitrocellulose membranes.
Membranes were saturated with 5% wt/vol nonfat dried milk to re-
duce nonspecific binding, then incubated with LO32 anti–5-LO anti-
body (20), 1:400 dilution, or H4 anti-FLAP antibody, 1:400 dilution,




15 min in Tween-20 Tris-
buffered saline (TBS) containing 0.1% vol/vol fish skin gelatin and in-
cubated for 1 h with goat anti–rabbit antiserum conjugated with
horseradish peroxidase (1:100,000 in Tween-20 TBS containing 1%




15 min in TBS
Triton X-100, 0.1% vol/vol, containing 0.1% vol/vol fish skin gelatin.
Membranes were incubated with enhanced chemiluminescence re-
agents for 60 s and exposed with Kodak XAR-5 film. ATP purified 5-LO
enzyme (24) was used as a standard on each gel. Film images ob-
tained from Western blotting were processed on a Molecular Dynam-
ics Computing Densitometer Model 300A scanning unit and the re-
sulting densitometry data analyzed using Molecular ImageQuant 3.0
software (Molecular Dynamics Inc., Sunnyvale, CA).
 










To assess the specificity of the FLAP inhibitor (18) on 5-LO
product formation by the isolated lung, the rat lung perfused with
Earle’s balanced salt solution (EBSS) was used as described below,
 






 M) was added to the perfu-
sate. Lung perfusion was stopped 10 min after addition of A23187









 by ELISA (25).
 
Effect of MK-886 on lung vascular reactivity.
 
The isolated rat lung,
perfused with a physiological salt solution, is a convenient prepara-
tion to assess the effects of naturally occurring mediators or drugs on
lung vasomotor tone (26). Lungs were isolated from male Sprague-
Dawley rats, perfused with EBSS at a constant perfusate flow of
0.3 ml/kg per min, and ventilated either with a gas mixture which con-

















). After a preincubation and equilibra-
tion period of 30 min, pulmonary vasoconstriction was elicited by in-




g) into the pulmonary artery line or
by switching the ventilation gas mixture from room air to 0% oxygen
(hypoxic pressor response). After two pairs of A II and hypoxia-
induced pressor responses, the FLAP ligand, MK-886 (Dr. Jilly Evans,
Merck-Frosst, Pointe Claire-Dorval, Canada) was added to the perfu-
sate reservoir; and 10 min after MK-886 addition, the pressor re-







 M) were examined. The data were compared with time-
matched controls perfused with DMSO only.
 
Effect of chronic MK-886 treatment on the development of hy-
poxia-induced pulmonary hypertension.
 
The degree of pulmonary hy-
pertension due to hypobaric hypoxia after chronic (28 d) exposure in
a high altitude chamber was assessed in two groups of rats: rats




l DMSO) or rats




l DMSO vehicle via single daily i.p. injection. Rats were
exposed to a simulated altitude of 16,000 ft. for 28 d, then removed
from the chamber for measurement of the pulmonary artery pressure
(3, 4). Subsequently, the animals were killed, and the hematocrit and
the ratio of right ventricle wt/left ventricle and septum wt as an index
of right heart hypertrophy were measured.
 
Development of right ventricular hypertrophy in chronically hy-
poxic 5-LO knockout mice.
 
5-LO–deficient (22) and normal control
congenic mice were exposed to hypobaric hypoxia as described
above. At the end of the exposure time, the animals were removed
from the high altitude chamber, killed, and the hematocrit and the ra-
tio of right ventricular wt/left ventricle plus septum wt were measured.









of differences observed between experimental treatment groups was












Immune localization of 5-LO and FLAP in rat lungs.
 
The anti–
5-LO antibody (LO32) stained alveolar macrophages in lungs
from normoxic rats. The anti–5-LO antibody (LO32) stained
alveolar macrophages and also small artery endothelial cells
(Fig. 1) in lungs from animals exposed to hypoxia for 4 wk.
The endothelial cell 5-LO staining did not occur with the lung
sections from hypoxic rats when anti–5-LO was preabsorbed
Figure 1. Immunohistochemical localization of 5-LO in rat lungs. Endothelial cells lining a large pulmonary artery in a 4-wk hypoxic rat lung ex-
press 5-LO (a, arrows, immunoperoxidase 3400), whereas no 5-LO immunoreactivity is present in the normoxic rat lung (b, immunoperoxidase, 
3400). Small pulmonary arteries in 4-wk hypoxic rat lungs exhibit 5-LO immunoreactivity localized to endothelial cells (c, arrowheads) but not 
to alveolar septa or vascular smooth muscle cells. In addition, alveolar macrophages also exhibit 5-LO (d, arrows) (c and d, immunoperoxidase, 
3200). Immunoreactivity of 5-LO present predominantly in alveolar macrophages in 4-wk hypoxic rat lungs (e, arrows) is completely abrogated 






with purified 5-LO protein. FLAP expression was increased in
the 4-wk hypoxic rat lung when compared with normoxic con-
trols. FLAP was predominantly localized in the endothelial
cells of small- and medium-sized pulmonary arterioles and in
alveolar and interstitial macrophages. Focal FLAP immu-
nostaining was also present in alveolar septa, probably within




Sections from control rat lungs and
from the lungs of rats which were exposed to hypobaric hy-
poxia for 3, 7, and 28 d were examined. The specific antisense
probe revealed 5-LO–mRNA labeling of alveolar macrophages.
There appeared to be no significant difference in the fre-
quency or intensity of the signal of labeled cells between con-
trol and hypoxic lungs. Notably, there was no specific labeling
of endothelial cells in any of the lung sections (Fig. 3). These
results were confirmed in three independent experiments.
Western analysis of 5-LO and FLAP in rat lung. Immuno-
blotting confirmed the presence of 5-LO in lungs from normoxic








) depicts 5-LO in total protein
samples prepared from rat lung tissue. Comparison of nor-









that total 5-LO content of lung tissue was diminished after 4 wk
of hypobaric hypoxia. Analysis by densitometry established




) was 2.0-fold greater than that seen




). To determine the intracellular
distribution of 5-LO in lung tissue, cytosol and membrane frac-






















brane fraction. This conclusion was substantiated by densitom-
etry. In the control, membrane fraction 5-LO was 6.1-fold




). Similarly, after 4 wk




), 5-LO in the membrane fraction
was 8.6-fold greater than the corresponding cytosolic fraction.
Comparison of the upper panel total protein samples and the
5-LO distribution samples shows a consistent pattern of dimin-
ished 5-LO in hypoxic rat lung. These differences are 2.0-fold
in total protein, 2.6-fold in cytosol, and 1.9-fold in membrane
samples. In contrast, FLAP was increased 2.7-fold over control





A 1.4-fold increase in FLAP protein was observed in hypoxic















 and pulmonary vasoconstriction in vitro.
 
Addition of MK-
Figure 2. Immunohistochemical localization of FLAP in rat lungs. (a) Normoxic lung does not express detectable FLAP in endothelial cells in 
pulmonary vessels (V), or in circulating inflammatory cells. (b) Mononuclear cells (arrowheads) located in the perivascular region of 4-wk hy-
poxic rat lung express FLAP. Endothelial cells (arrow) in pulmonary vessels (V) also express reactivity with FLAP antibody. (c) 4-wk hypoxic 
lung with strong reactivity for FLAP in endothelial cells (arrows). Note focal expression of FLAP in alveolar septa (a, b, c, Immunoperoxidase, 
3400). Normal rabbit serum control (d) in a 4-wk hypoxic lung. In contrast to the 5-LO (Fig. 1 b) and FLAP (Fig. 2 c) immunostaining observed 
in the hypoxic 4-wk lung, no immunoreactivity is evident in the pulmonary artery (V), alveolar septa (S), perivascular inflammatory cells (arrow) 
or bronchiolar lining cells (b, Immunoperoxidase, 3200).
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886 (1025 M) to the perfusate of the isolated lungs 10 min be-
fore challenge with A23187 (1025 M) reduced the perfusate
content of LTB4 but had no effect on thromboxane B2 (data
not shown). Because MK-886 at 1025 M selectively inhibited
A23187-triggered LT production, this concentration was used
to modulate the vasoconstrictor response to angiotensin II, al-
veolar hypoxia, and PMA, in vitro. Perfusate concentrations
lower than 1025 M MK-886 did not affect pulmonary vasocon-
striction; however, 1025 M MK-886 significantly reduced the
angiotensin II–induced pressor response (4.561 mmHg vs.
1161 mmHg, P , 0.05) and the hypoxic pressor response
(1.561 mmHg vs. 1161 mmHg, P , 0.05). The more gradually
developing vasoconstriction which occurred after addition of
PMA (1028 M) to the perfusate was unaltered by MK-886
(1025 M) (1862 mmHg vs. 2062 mmHg) indicating that it had
not acted as a vasodilator.
Effect of chronic MK-886 on chronic pulmonary hyperten-
sion. When rats received daily injections of MK-886 (30 mg/kg,
i.p.), the degree of pulmonary hypertension and right ventricu-
lar hypertrophy was less at the end of the 4 wk of chronic hy-
pobaric hypoxia compared to rats treated identically with
DMSO vehicle (Fig. 5, A and B).
Right ventricular hypertrophy in 5-LO knockout mice.
Chronic hypobaric hypoxia resulted in a reduced right ventricle
wt/left ventricle plus septum (RV/LV 1 S) wt ratio in the 5-LO
knockout mice (0.3260.01) when compared to the 5-LO com-
petent control mice (0.4760.03, P , 0.05) (Fig. 6).
Discussion
The cellular sites of 5-LO gene expression and the intracellular
distribution of the 5-LO were investigated in lung tissues ob-
tained from normal and chronically hypoxic, pulmonary hy-
pertensive rats. In situ hybridization shows that macrophages
are the major cell source for 5-LO in the rat lung, and our im-
munohistology studies support this conclusion. Immunochemi-
cal data show that chronic hypoxia and pulmonary hypertension
provide conditions favoring cytosol to membrane translocation
of the 5-LO and conditions for detection of 5-LO in lung en-
dothelial cells. In addition, chronic hypoxia and/or chronic pul-
monary hypertension leads to an increase in FLAP protein in
Figure 3. In situ hybridization for 5-LO mRNA in hypoxic rat lungs. 
(a) Note intense hybridization signal for 5-LO transcripts in alveolar 
macrophages (arrows) but not in endothelial cells of a small pulmo-
nary artery (v). (b) The hybridization signal is absent in parallel sec-
tions hybridized with the sense control probe. (3400).
Figure 4. (a) Western analysis of 5-LO obtained from rat lung tissue. 
Equal quantities of protein, 10 mg/lane, prepared from frozen rat lung 
tissue were separated on 10% acrylamide gels under reducing condi-
tions. Top, comparison of total 5-LO enzyme in rat lung tissue. Lane 1, 
control rat lung tissue. Lane 2, 4-wk hypoxic rat lung tissue. A 78-kD 
5-LO standard is shown to the left of the treatment groups. Bottom, 
comparison of 5-LO distribution in rat lung tissue cytosol and mem-
brane fractions. The amount of membrane-associated enzyme is de-
picted directly below the amount of cytosolic enzyme. Lane 1, control 
rat lung tissue. Lane 2, 4-wk hypoxic rat lung tissue. A 78-kD 5-LO 
standard is shown to the left of the treatment groups. (b) Western 
analysis of FLAP obtained from rat lung tissue. Equal quantities of 
protein, 10 mg/lane, prepared from frozen rat lung tissue were sepa-
rated of a 15% acrylamide gel under reducing conditions. Lane 1, 
control rat lung tissue. Lane 2, 4-wk hypoxic rat lung tissue. Lane 3, 
MK-886-treated 4-wk hypoxic rat lung tissue.
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the lungs. Assessment of the role of 5-LO in the lung based on
treatment of isolated perfused lungs or of chronically hypoxic
rats with MK-886, an antagonist of FLAP:5-LO interactions,
supports the conclusion that the 5-LO activity contributes to
lung vascular tone regulation and plays a role in the develop-
ment of pulmonary hypertension. The observation that 5-LO–
deficient (5-LO knockout) mice (22) exposed to hypoxia de-
velop less right heart hypertrophy than congenic control mice
which possess a functional 5-LO gene is also consistent with
this conclusion.
In normoxic and hypoxic animals 5-LO occurs prominently
in macrophages; however, in the chronically hypoxic, hyper-
tensive lungs, the anti–5-LO antibody also labeled small vessel
endothelial cells (Fig. 1). We emphasize that this staining did
not occur in lungs from normoxic control rats, and preabsorp-
tion of the antibody with purified 5-LO protein abolished both
Figure 5. Daily i.p. injection of MK-886 decreases the 
mean pulmonary artery pressure (Ppa) (A) and the 
degree of right heart hypertrophy [wt of the right 
ventricle/wt of left ventricle plus septum] (B) after 
4-wk of hypobaric hypoxia (simulated altitude of 
16,000 ft) when compared to hypoxic rats treated 
with solvent (DMSO).
Figure 6. Effect of exposure of 5-LO 
competent (5-LO comp) and 5-LO–
deficient mice to 3 wk of hypobaric 
hypoxia. Control animals were housed 
at 5,280 ft (Denver, CO). Shown are 
individual animal data for the ratio of 
the right ventricular wt/left ventricle 
plus septum wt (RV/LV 1 S).
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macrophage and endothelial cell labeling in control or chroni-
cally hypoxic lungs. One plausible explanation for this novel
observation is that LO32 detects a 5-LO isozyme. Although the
current consensus is that isolated endothelial cells are unable
to produce LT (13) via 5-LO activation, Claesson et al. (12)
observed that human umbilical cord vein–derived endothelial
cells produced both LTC4 and LTB4 after addition of LTA4,
provided that the cells had been cultured for 10–16 d; freshly
isolated cells did not metabolize LTA4. This implies that a phe-
notype switch may occur during culture. By analogy, hypoxia
affects gene expression in cultured endothelial cells (16, 17)
and in isolated perfused lungs (27). Thus, we speculate that
during chronic hypoxia and/or under the influence of increased
shear stress and cytokine release some lung vascular endothe-
lial cells acquired a phenotype which can express a form of 5-LO
or a protein with an epitope recognized by antibody LO32. Of
interest is a report which demonstrates that HL-60 cells and
brain tumors contain several 5-LO transcripts (28). Our in situ
gene expression studies demonstrate that the 5-LO mRNA is
not expressed abundantly in lung cells. This conforms with the
report of Kaneko et al. (11) showing that lung tissue contained
approximately one-tenth of the neutrophil 5-LO activity.
Chronic hypoxia did not increase lung 5-LO protein, ac-
cording to our in situ hybridization and Western blot data.
However, 4 wk of chronic hypoxia caused a detectable shift of
5-LO from the cytosol to the membrane fraction of lung ho-
mogenate (Fig. 4 a). If most of the lung tissue 5-LO is localized
to macrophages, then this 5-LO translocation may have origi-
nated from or contributed to the hypertensive phenotype. In
resting alveolar macrophages, 5-LO is mainly associated with
the membrane fraction (29). Our data with normoxic lungs are
consistent with the earlier finding by Coffey et al. (29). The
translocation of the residual, cytosolic 5-LO to the membranes
may constitute part of the mechanism of lung 5-LO activation
in chronic hypoxia/pulmonary hypertension. Alternatively,
chronic hypoxia may enhance interactions between 5-LO and
the membrane via the stoichiometric excess of FLAP or via
other macromolecules. Increased intracellular calcium induced
by chronic hypoxia (30) may also have contributed to 5-LO
translocation in the lung cells. This is also likely the cause of
hypoxia- and angiotensin II–induced pulmonary vasoconstric-
tion (31).
In contrast to the 5-LO protein, which did not increase dur-
ing chronic hypoxia/pulmonary hypertension, FLAP was more
abundant in lungs from chronically hypoxic rats. Thus, in rat
lungs, under the conditions of hypoxia-induced pulmonary hy-
pertension, the role of the 5-LO system may involve both its
translocation and increased FLAP availability. MK-886, an an-
tagonist of FLAP:5-LO binding, affected both the magnitude
of acute hypoxic vasoconstriction and the development of
chronic pulmonary hypertension. Both pulmonary artery pres-
sure and right heart hypertrophy were decreased in rats chron-
ically treated with daily injections of MK-886. Two structurally
distinct inhibitors of LT formation, diethylcarbamazine (9)
and CGS22745 (10), had previously been shown to inhibit the
development of chronic hypoxic pulmonary hypertension in
rats. Whether MK-886 inhibited the development of chronic
pulmonary hypertension because of direct inhibition of hy-
poxia-induced pulmonary vasoconstriction or because of inhi-
bition of vascular remodeling was not investigated in the
present study.
In summary, rats that demonstrate pulmonary hyperten-
sion and vascular remodelling after chronic exposure to high al-
titude provide evidence for: (a) a redistribution of cellular 5-LO
protein from the soluble cytosolic fraction to the membrane
particulate fraction, (b) an increase in immunologically detect-
able FLAP protein, and (c) the appearance of 5-LO protein in
vascular endothelial cells. The redistribution of cellular 5-LO
in the presence of increased FLAP protein may represent aug-
mented vascular cell activity in hypertensive lung tissue. Al-
though the effect that 5-LO inhibitors have on the develop-
ment of chronic hypertension has not been extensively studied
and reported on, studies that have examined the effect of vari-
ous 5-LO inhibitors and leukotriene antagonists have pro-
duced inconsistent results (for review see references 32, 33).
These conflicting reports suggest that the participation of 5-LO
in the development of this condition may involve both an en-
zymatic component associated with leukotriene production
and a nonenzymatic component determined by interactions
between 5-LO and other macromolecules involved in cellular
activation. The data presented in this work and a recent com-
munication (34) provide the first evidence that demonstrates
that a 5-LO FLAP-binding antagonist, MK-886, alters vasocon-
striction in perfused rat lungs. The strength of this evidence
rests upon the use of a well established preparation for the
study of pulmonary vascular tone and the selectivity of MK-886
as used in this preparation. Although models which describe
inhibition of the monovalent current carried by a potassium
channel have been advanced to provide a mechanistic basis for
hypoxic pulmonary vasoconstriction (35, 36, 37), evidence link-
ing MK-886 to cellular ion gated channel activity is lacking at
present. In conclusion, the data presented indicate that 5-LO
participates in modulating lung vascular tone and possibly in
the remodelling of lung vasculature.
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